For research use only. Not for therapeutic Use.
Iferanserin (S-MPEC) is a selective 5-HT receptor (serotonin receptor) antagonist with an affinity for 5-HT2A receptor. Iferanserin has the potential for internal hemorrhoid disease treatment[1].
An intra-anal ointment application of Iferanserin might modify the vascular effects occurring in hemorrhoid disease and thereby reduce or eliminate the most frequently occurring symptoms of hemorrhoid disease[1].
| Catalog Number | I007268 |
| CAS Number | 58754-46-4 |
| Synonyms | (E)-N-[2-[2-[(2S)-1-methylpiperidin-2-yl]ethyl]phenyl]-3-phenylprop-2-enamide |
| Molecular Formula | C23H28N2O |
| Purity | ≥95% |
| InChI | InChI=1S/C23H28N2O/c1-25-18-8-7-12-21(25)16-15-20-11-5-6-13-22(20)24-23(26)17-14-19-9-3-2-4-10-19/h2-6,9-11,13-14,17,21H,7-8,12,15-16,18H2,1H3,(H,24,26)/b17-14+/t21-/m0/s1 |
| InChIKey | UXIPFQUBOVWAQW-UEBLJOKOSA-N |
| SMILES | CN1CCCCC1CCC2=CC=CC=C2NC(=O)C=CC3=CC=CC=C3 |
| Reference | [1]. Herold A, et al. Intra-anal Iferanserin 10 mg BID for hemorrhoid disease: a prospective, randomized, double-blind, placebo-controlled trial. Clin Ther. 2012 Feb;34(2):329-40. |
